I aggressively use a constantly updated OAB Care Pathway to increase 3rd line penetration and intermittently analyze my ICD and CPT codes to monitor changes in therapy selection given new offerings in addition to evaluating the impact of unprecedented pandemic restrictions and telemedicine implementation. During...
A PMA supplement for the newest implantable neurostimulator (INS) was approved by the FDA. This marks the 6th FDA approval Axonics has been granted for a product innovation since November 2019. The newest INS has upgraded embedded software that improves the Key-fob remote functionality. Specifically,...
In December 2020, Urovant gained FDA approval of its NDA (New Drug Application) for once-daily 75mg GEMTESA® (vibegron), which is a beta-3 receptor agonist. The medication will be available April 2021. The onset of action is faster like current anti-cholinergics without the often-intolerable side effects...
In a recent publication, Bulkamid injections for SUI were found to be efficacious, safe and durable. The January 2021 issue of Neurourology and Urodynamics reports 7-year outcomes in 388 patients. Positive results of this minimally invasive option include 81% of patients being satisfied with no...
Based on input from many patients Axonics redesigned their recharging belt to optimize patient experience. The curved design offers improved ergonomic fit (Shown Below) and offers an enhanced charging experience. IPG placement moved from a lateral pocket placement to a medial pocket placement based on...